摘要
银屑病是长期性的慢性炎症性皮肤病,患者基数多,市场大,属于国内外科研人员研究的重要方向。本文利用专利信息以及药物注册信息对银屑病药物的发展状况进行了分析。结果表明,银屑病治疗药物开始逐步从化学药向生物药进行过渡,抗体类药物是目前研发的热点方向,特别是TNF靶点以及IL靶点更是热门中的焦点。本文还对制药企业提出了相应的发展建议。
Psoriasis is a chronic inflammatory dermatosis with a large number of patients and a large market.It is an important research field for domestic and foreign researchers.In this paper,the development of psoriasis drugs is analyzed by using patent information and drug registration information.The results shows that psoriasis drugs begin to change gradually from chemical drugs to biological drugs.The research of antibody drugs is a key focus area,especially TNF and IL targets.This paper also puts forward some suggestions for the development of pharmaceutical enterprises.
引文
[1]Rizvi S,Chaudhari K,Syed B A.The psoriasis drugs market[J].Nat Rev Drug Discov,2015,14(11):745-746.
[2]陈明,钟杰敏,刘冠萍等.银屑病治疗靶点及其药物研发进展[J].2015(9):846-850.